...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

A $3 per share price, American, would be fine with me. The accumulated tax loss plus the science learned and in the data base would make this a “piece of cake” for Big Pharma.

Time to move on...especially if we have enough money to get to November 16 and we learn about some great secondary end points.

Share
New Message
Please login to post a reply